LivaNova (NASDAQ:LIVN) Lowered to Buy Rating by StockNews.com

LivaNova (NASDAQ:LIVN) was downgraded by research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a note issued to investors on Wednesday.

LIVN has been the subject of several other research reports. Baird R W raised LivaNova from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 17th. Robert W. Baird raised their price target on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. The Goldman Sachs Group initiated coverage on LivaNova in a research note on Friday, October 4th. They issued a “buy” rating and a $65.00 price objective on the stock. Mizuho lowered their target price on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, October 31st. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $75.00 target price on shares of LivaNova in a research note on Monday, November 25th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $69.17.

LivaNova Price Performance

LIVN stock opened at $47.06 on Wednesday. The company’s 50-day moving average price is $51.20 and its two-hundred day moving average price is $50.89. The firm has a market cap of $2.56 billion, a P/E ratio of 112.05 and a beta of 0.98. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. LivaNova has a 12 month low of $43.15 and a 12 month high of $64.47.

Insider Activity at LivaNova

In related news, Director Francesco Bianchi sold 1,250 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the transaction, the director now directly owns 7,522 shares of the company’s stock, valued at $383,546.78. This trade represents a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.27% of the stock is currently owned by insiders.

Hedge Funds Weigh In On LivaNova

Hedge funds and other institutional investors have recently modified their holdings of the business. Sanctuary Advisors LLC bought a new stake in shares of LivaNova during the 3rd quarter worth $219,000. Geode Capital Management LLC boosted its holdings in LivaNova by 0.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,344,949 shares of the company’s stock worth $70,676,000 after buying an additional 8,331 shares during the period. XTX Topco Ltd bought a new position in shares of LivaNova in the third quarter worth $550,000. Point72 DIFC Ltd grew its position in shares of LivaNova by 75,799.6% in the third quarter. Point72 DIFC Ltd now owns 181,400 shares of the company’s stock valued at $9,531,000 after purchasing an additional 181,161 shares in the last quarter. Finally, Point72 Asset Management L.P. increased its position in shares of LivaNova by 62.7% during the third quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company’s stock valued at $109,914,000 after buying an additional 806,374 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.